Has tucatinib/tucatinib been launched in China?

Tucatinib/Tucatinib (Tucatinib) is a new generation of small molecule targeted drugs for HER2-positive cancers, developed by the American company Seagen. It is a third-generation HER2 tyrosine kinase inhibitor (TKI) that is highly selective at the molecular level and can effectively inhibit the HER2 signaling pathway, thereby blocking the growth and spread of cancer cells. Since its approval in the United States in 2020, tucatinib has become one of the important treatment options for patients with HER2-positive breast cancer and brain metastases, and is considered a major breakthrough in the field of HER2-targeted therapy.

As of now, tucatinib has not been officially approved for marketing in China. According to the public registration information of the National Medical Products Administration (NMPA), there is no record of TUKYSA (tucatinib) obtaining marketing approval in China. This means that there is still no legal sales of tucatinib original drug in domestic hospital pharmacies and drug distribution channels. Although some medical institutions in China have participated in international multi-center clinical studies of this drug, these are only in the scientific research stage and have not yet entered commercial application. It is worth noting that some patients may obtain generic tucatinib drugs produced in Laos and Bangladesh through overseas channels. The chemical structure of these drugs is basically the same as the original drug.

From a therapeutic perspective, the core advantage of tucatinib lies in its "high selectivity" targeting of HER2 without almost affecting the EGFR pathway. This allows patients to obtain curative effects while having a relatively low risk of side effects such as rash and diarrhea. In addition, it has good blood-brain barrier penetration and can be used to treat patients with brain metastases from HER2-positive breast cancer. This feature is of great clinical significance among HER2 drugs. Overseas research results show that the treatment regimen of tucatinib combined with trastuzumab and capecitabine significantly prolongs progression-free survival and shows good efficacy in patients with brain metastases. Therefore, it is recommended by multinational oncology guidelines as an important option for HER2-positive metastatic breast cancer.

Reference materials:https://www.tukysa.com/